Hookipa Pharma (NASDAQ:HOOK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “

A number of other analysts also recently issued reports on HOOK. Bank of America raised Copa from a “neutral” rating to a “buy” rating in a research report on Monday, May 13th. Leerink Swann initiated coverage on Turning Point Therapeutics in a research report on Monday, May 13th. They issued an “outperform” rating and a $42.00 target price on the stock. Svb Leerink initiated coverage on Hookipa Pharma in a research report on Monday, May 13th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada lifted their target price on NVIDIA to $200.00 and gave the company an “outperform” rating in a research report on Monday, May 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $20.00.

Shares of HOOK traded up $0.09 during midday trading on Wednesday, hitting $7.25. The stock had a trading volume of 9,737 shares, compared to its average volume of 244,917. The firm has a 50 day moving average of $7.59. Hookipa Pharma has a twelve month low of $6.06 and a twelve month high of $14.76.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings results on Monday, May 20th. The company reported ($9.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($8.85). The business had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $0.50 million. Research analysts expect that Hookipa Pharma will post -2.14 EPS for the current year.

In other Hookipa Pharma news, insider Bros. Advisors Lp Baker purchased 892,857 shares of Hookipa Pharma stock in a transaction that occurred on Tuesday, April 23rd. The stock was acquired at an average price of $14.00 per share, for a total transaction of $12,499,998.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Sofinnova Capital Vi Fcpr purchased 357,142 shares of Hookipa Pharma stock in a transaction that occurred on Tuesday, April 23rd. The shares were acquired at an average price of $14.00 per share, with a total value of $4,999,988.00. The disclosure for this purchase can be found here.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also: Range Trading

Get a free copy of the Zacks research report on Hookipa Pharma (HOOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.